Alaunos Therapeutics announces board member resignation

Alaunos Therapeutics, Inc. (NASDAQ:TCRT), a pharmaceutical company specializing in the development of cancer treatments, disclosed the resignation of Dr. Robert Hofmeister from its board of directors. The departure, which took effect immediately on April 15, 2025, was reported in a filing with the Securities and Exchange Commission on Friday. The announcement comes as the company’s stock has declined 15% over the past week, though it maintains a 30% gain year-to-date. According to InvestingPro, the company currently shows signs of being undervalued based on its Fair Value analysis.

Dr. Hofmeister’s decision to step down from the board was not due to any disagreements with the company regarding its operations, policies, or practices, according to the statement. The company has not yet announced a successor or provided details on the process for filling the now-vacant board seat.

The Houston-based company, formerly known as ZIOPHARM Oncology Inc., operates under the industrial classification of Pharmaceutical (TADAWUL:2070) Preparations. Alaunos Therapeutics is incorporated in Delaware and maintains its principal executive offices in Texas.

Investors and market watchers will be observing the company’s next steps in this period of transition. The departure of a board member can signal changes within a company’s governance structure, although in this instance, there has been no indication of underlying issues prompting the resignation.

The announcement was made in compliance with SEC regulations and represents a routine disclosure of corporate governance matters. The company’s stock, TCRT, is listed on The Nasdaq Stock Market LLC.

This report is based on a press release statement filed with the SEC and does not contain any additional insights or analysis.

In other recent news, Alaunos Therapeutics, Inc. has raised $500,000 through a private placement agreement involving the sale of preferred stock. The transaction was completed with Watermill Asset Management, which purchased the Series A-1 Convertible Preferred Stock. Each share of this newly issued stock is priced at $1,000 and carries a 10% annual dividend, payable in additional shares of the same class. The preferred stockholders are granted voting rights equivalent to common stockholders and can convert their shares into common stock at a fixed rate of $2.76 per share. This financial strategy is part of Alaunos Therapeutics’ efforts to secure funding for its operations. The securities involved in this offering have not been registered under the Securities Act of 1933 and were offered under an exemption from registration requirements. As a result, these securities cannot be resold in the U.S. without registration or an applicable exemption. This move also modifies the rights of security holders, as detailed in the Certificate of Designation filed with the Delaware Secretary of State.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.